Antibiotic pills swirling around a healthy immune system nebula.

Battling Superbugs: Can a Smart Antibiotic Strategy Help Patients in Need?

Lena Voss in Health & Wellness December 2025 • 4 min read.

"Exploring the impact of alternating antibiotic treatments on febrile neutropenia, a dangerous condition affecting those undergoing cancer treatments, and why a balanced approach may be key."

The rise of antibiotic-resistant bacteria poses a significant threat to modern medicine, turning once-treatable infections into life-threatening conditions. This is especially critical for individuals with weakened immune systems, such as those undergoing chemotherapy for cancer. Febrile neutropenia, a common complication in these patients, occurs when their white blood cell count drops, making them highly susceptible to infections. The standard approach involves using empirical antibiotics—powerful drugs administered before the specific infection is identified.

However, the overuse of single, go-to antibiotics breeds resistance, limiting treatment options. Experts are now exploring alternative strategies, one of which involves promoting antibiotic heterogeneity—essentially, "mixing" things up to prevent bacteria from adapting. The goal is not only to treat infections effectively but also to slow down the march of resistance, preserving the effectiveness of our current arsenal of drugs.

A recent study published in PLOS ONE delves into the impact of an alternating first-line antibiotic strategy on patients with febrile neutropenia. Researchers at Singapore General Hospital investigated whether changing the primary antibiotic used could reduce mortality and bacteremia rates, offering a beacon of hope in the fight against superbugs.

The 'Mixing' Strategy: A Balanced Approach to Antibiotics

Antibiotic pills swirling around a healthy immune system nebula.

The core concept revolves around creating a less predictable environment for bacteria. Instead of consistently using the same antibiotic, a 'mixing' strategy introduces variety, making it harder for bacteria to develop resistance to any single drug. Mathematical models suggest that heterogeneous antibiotic use can significantly reduce resistance emergence.

Researchers implemented an alternating first-line antibiotic strategy in mid-2013. They compared data from 2012 (before the strategy) with data from 2014 (after implementation). On odd days, patients received piperacillin-tazobactam (PTZ), and on even days, they received a cefepime-amikacin (CEF-AMK) combination. The goal was to alternate the selection pressure on bacteria, preventing them from becoming resistant to a single, dominant antibiotic.

Reduced Cefepime Usage: The defined daily doses (DDD) of cefepime (CEF) decreased in 2014 compared to 2012.
Increased Piperacillin-Tazobactam Usage: The defined daily doses (DDD) of piperacillin-tazobactam (PTZ) rose in 2014 compared to 2012.
Vancomycin Use Decreased: The use of Vancomycin decreased in 2014, with a fall in defined daily doses (DDD).
Increased Antibiotic Heterogeneity Index (AHI): The Antibiotic Heterogeneity Index (AHI) increased from 0.466 in 2012 to 0.582 in 2014.

The study found that the alternating antibiotic strategy increased antibiotic heterogeneity without significantly increasing mortality. There was also no significant difference in bacteremia rates or in the rates of CEF-resistant, PTZ-resistant, and carbapenem-resistant gram-negative organisms. Furthermore, the rates of new MRSA and VRE cases remained stable. This suggests that the 'mixing' strategy could be a safe and effective way to manage antibiotic use in febrile neutropenia.

A Promising Step Forward

While further research is needed, this study suggests that an alternating first-line antibiotic strategy can be a valuable tool in combating antibiotic resistance in vulnerable populations. By carefully 'mixing' antibiotics, we can reduce the selective pressure that drives resistance, preserving the effectiveness of these life-saving drugs. As superbugs continue to evolve, innovative strategies like this will be crucial in protecting patients and ensuring a healthier future for all.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1371/journal.pone.0208039, Alternate LINK

Title: Impact Of An Alternating First-Line Antibiotics Strategy In Febrile Neutropenia

Subject: Multidisciplinary

Journal: PLOS ONE

Publisher: Public Library of Science (PLoS)

Authors: Ban Hock Tan, Marvin Raden Torres De Guzman, Lara Kristina Sioco Donato, Shirin Kalimuddin, Winnie Hui Ling Lee, Ai Ling Tan, Gee Chuan Wong

Published: 2018-11-28

Everything You Need To Know

What exactly is febrile neutropenia, and why is it such a concern?

Febrile neutropenia is a dangerous condition that primarily affects individuals with weakened immune systems, such as those undergoing chemotherapy for cancer. It occurs when their white blood cell count drops, making them highly susceptible to infections. This condition is significant because it can quickly become life-threatening if not treated promptly and effectively, often requiring the use of empirical antibiotics to combat potential infections before they are fully identified.

What are empirical antibiotics, and why are they used so often in treating infections?

Empirical antibiotics are powerful drugs administered to patients with febrile neutropenia before the specific infection is identified. They are significant because they provide immediate protection against potential infections in vulnerable patients. However, the overuse of empirical antibiotics can lead to antibiotic resistance, limiting treatment options in the future. This makes balancing immediate treatment needs with long-term antibiotic stewardship crucial.

Can you explain what the 'mixing' strategy is all about and why it could be useful?

The 'mixing' strategy, also known as antibiotic heterogeneity, involves alternating the antibiotics used to treat infections. The goal is to create a less predictable environment for bacteria, making it harder for them to develop resistance to any single drug. This is important because it can slow down the emergence of antibiotic-resistant bacteria, preserving the effectiveness of our current arsenal of drugs and ensuring better treatment outcomes for patients.

What is the Antibiotic Heterogeneity Index (AHI), and why is it important to track?

The Antibiotic Heterogeneity Index (AHI) is a metric used to measure the diversity of antibiotics used in a specific setting. It's significant because a higher AHI indicates a greater variety of antibiotics being used, which can help reduce the selective pressure on bacteria and slow down the development of resistance. Monitoring the AHI allows healthcare professionals to assess the effectiveness of antibiotic stewardship strategies and make informed decisions about antibiotic use.

How did the alternating antibiotic strategy work in practice with the antibiotics that were used?

The study implemented an alternating first-line antibiotic strategy involving piperacillin-tazobactam (PTZ) on odd days and a cefepime-amikacin (CEF-AMK) combination on even days. This strategy aimed to alternate the selection pressure on bacteria, preventing them from becoming resistant to a single, dominant antibiotic. This approach is significant because it represents a practical method for increasing antibiotic heterogeneity in clinical settings, potentially reducing the development of antibiotic resistance without negatively impacting patient outcomes.